NTRA · Natera, Inc.
AI read · Good for NTRA
The AI's read
More tests were processed, and growth came from both clinical and pharma products. That points to activity across several parts of Natera's business. The leadership switch adds some risk, but Moshkevich has led key oncology work, and Chapman will remain a consultant and board adviser. The reported business growth outweighs that concern.